Blair William & Co. IL Sells 16,259 Shares of Hologic, Inc. $HOLX

Blair William & Co. IL reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 22.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 55,560 shares of the medical equipment provider’s stock after selling 16,259 shares during the quarter. Blair William & Co. IL’s holdings in Hologic were worth $3,620,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Greenleaf Trust lifted its position in shares of Hologic by 5.1% during the 2nd quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock valued at $233,000 after buying an additional 173 shares in the last quarter. Beverly Hills Private Wealth LLC increased its position in shares of Hologic by 3.6% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider’s stock valued at $320,000 after purchasing an additional 180 shares during the last quarter. Allworth Financial LP increased its position in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 216 shares during the last quarter. First American Bank increased its position in shares of Hologic by 0.9% during the 2nd quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock valued at $1,870,000 after purchasing an additional 245 shares during the last quarter. Finally, Townsquare Capital LLC increased its position in shares of Hologic by 4.5% during the 1st quarter. Townsquare Capital LLC now owns 6,763 shares of the medical equipment provider’s stock valued at $418,000 after purchasing an additional 293 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

Shares of Hologic stock opened at $65.51 on Tuesday. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39. The company has a market cap of $14.57 billion, a price-to-earnings ratio of 27.18, a PEG ratio of 2.32 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The business’s 50 day moving average price is $67.10 and its 200 day moving average price is $63.36.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter last year, the business posted $1.06 earnings per share. The firm’s revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Evercore ISI set a $78.00 target price on Hologic and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Royal Bank Of Canada raised Hologic from a “sector perform” rating to an “outperform” rating and raised their target price for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Mizuho set a $75.00 target price on Hologic in a research report on Thursday, July 31st. Finally, Stephens restated an “overweight” rating and issued a $78.00 target price on shares of Hologic in a research report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $80.15.

Insider Buying and Selling

In related news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.88% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.